COVID-19 oral treatment listed on PBS from 1 May 2022

From 1 May 2022, Paxlovid will be available through the Pharmaceutical Benefits Scheme (PBS) for Australians at high risk of developing severe COVID-19.

Date published:
General public

This prescription-only oral treatment has been found to be effective in treating mild to moderate COVID-19 in adults aged 18 years of age and older, who do not require supplemental oxygen, and who are at increased risk of progressing to hospitalisation.

For more information about oral treatments for COVID-19, including Paxlovid.

Find out more about Paxlovid.

Download the PBS fact sheet

PBAC Web Outcome Statement: NIRMATRELVIR AND RITONAVIR (Paxlovid)

Consumer resources for Paxlovid on NPS MedicineWise

Help us improve

If you would like a response please use the enquiries form instead.